DOCSLIB.ORG

'Cartilage Hair Hypoplasia and the RMRP Gene'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
'Cartilage Hair Hypoplasia and the RMRP Gene' ‘Cartilage Hair Hypoplasia and the RMRP gene’ Ph.D. Thesis to accomplish Doctorate Degree in Science at the Faculty of Biology Johannes Gutenberg-University of Mainz in Mainz Pia Hermanns Mainz 2005 In memory of my mother Table of Contents Table of contents Index of Figures: ...............................................................................................................................V Index of Tables:..............................................................................................................................VII 1 Introduction.............................................................................................................................1 1.1 Skeletal development ...................................................................................................................1 1.2 Disorders of the Skeleton ............................................................................................................8 1.3 Cartilage Hair Hypoplasia ..........................................................................................................9 1.4 The RMRP gene.........................................................................................................................11 1.5 Specific Aims ..............................................................................................................................14 Methods..................................................................................................................................15 2.1 DNA isolation methods..............................................................................................................15 2.1.1 Genomic DNA isolation from whole blood (from February 2001 to December 2002) .......15 2.1.2 Genomic DNA isolation from whole blood (from January 2003 to present) .......................15 2.1.3 Isolation of genomic DNA from mouse tails for genotyping...............................................16 2.1.4 Isolation of genomic DNA from yeast cells .........................................................................17 2.1.5 Isolation of genomic DNA from ES cell clones for Mini-Southern analysis.......................17 2.1.6 Isolation of plasmid DNA ....................................................................................................18 2.1.6.1 Isolation of plasmid DNA from bacteria for subcloning...............................................................18 2.1.6.2 Isolation of plasmid DNA from bacteria for sequencing ..............................................................18 2.1.6.3 Isolation of plasmid DNA from bacteria for transfection .............................................................19 2.1.6.4 Isolation of plasmid DNA from yeast cells ...................................................................................19 2.2 Total RNA isolation ...................................................................................................................20 2.2.1 Isolation of total RNA from mammalian cells .....................................................................20 2.2.2 Isolation of total RNA from EDTA whole blood.................................................................20 2.2.3 Isolation of total RNA from Saccharomyces cereviseae ......................................................20 2.3. DNA and RNA standard methods...........................................................................................21 2.3.1 Electrophoresis methods.......................................................................................................21 2.3.1.1 Agarose gel electrophoresis for DNA............................................................................................21 2.3.1.2 Agarose gel electrophoresis for RNA............................................................................................21 2.3.1.3 PAA gel electrophoresis.................................................................................................................22 2.3.2 Purification of DNA fragments from agarose gels...............................................................22 2.3.2.1 Purification of DNA fragments < 10 kb from agarose gels ..........................................................22 2.3.2.2 Purification of DNA fragments >10 kb from agarose gels ...........................................................23 2.4 PCR techniques..........................................................................................................................23 2.4.1 Standard PCR .......................................................................................................................23 2.4.2 Long template PCR ..............................................................................................................24 2.4.3 Site-directed mutagenesis PCR ............................................................................................24 2.4.4 Reverse-Transcriptase ..........................................................................................................25 2.4.5 Quantitative PCR (Real-Time-PCR) ....................................................................................25 2.4.6 Subcloning of PCR products ................................................................................................26 2.5 DNA sequencing.........................................................................................................................26 2.5.1 Dye terminator reaction........................................................................................................26 2.5.2 Dye primer reaction..............................................................................................................27 2.6 Competent cells ..........................................................................................................................27 2.7 Transformation of DNA into bacteria cells .............................................................................27 I Table of Contents 2.8 Manipulation of yeast cells........................................................................................................28 2.8.1 High-efficiency transformation of Yeast..............................................................................28 2.8.2 Generation of yeast knockout construct ...............................................................................28 2.8.3 Sporulation and dissecting of tetrads....................................................................................29 2.8.4 PI staining of yeast cells for FACS analysis ........................................................................30 2.8.5 Phloxine B staining of yeast cells for FACS analysis ..........................................................30 2.8.6 Replica plating of yeast cells................................................................................................31 2.9 Transfection of adherent cells...................................................................................................31 2.10 Firefly luciferase assay in extracts prepared from transfected cells ...................................32 2.11 X-gal assays ..............................................................................................................................32 2.11.1 X-gal assay from cell extracts prepared from transfected cells..........................................32 2.11.2 X-gal staining of lacZ positive newborn mice....................................................................33 2.12 Labeling of DNA and RNA probes with isotopes..................................................................33 2.12.1 Random primed oligo labeling ...........................................................................................33 2.12.2 Endlabeling of chemically synthesized oligos....................................................................33 2.12.3 Labeling of in situ probes with S35 .....................................................................................34 2.13 Hybridization techniques ........................................................................................................35 2.13.1 Southern Hybridization ......................................................................................................35 2.13.2 Northern Hybridization ......................................................................................................35 2.13.2.1 Northern Hybridization with Agarose gels..................................................................................35 2.13.2.2 Northern Hybridization with Polacrylamide gels........................................................................36 2.13.3 In situ Hybridization...........................................................................................................36 2.14 Cell culture techniques ............................................................................................................37 2.14.1 Standard cell culture conditions for of adherent cells ........................................................37 2.14.2 Standard cell culture conditions for EBV transformed lymphoblasts ................................38 2.14.3 Subcloning ES cells for Mini-Southerns after electroporation and neomycin selection: ...38 2.15 Histology ...................................................................................................................................38 2.15.1 Tissue embedding in paraffin .............................................................................................38
Load more

Recommended publications
  • Cartilage-Hair Hypoplasia
    Cartilage-hair hypoplasia Description Cartilage-hair hypoplasia is a disorder of bone growth characterized by short stature ( dwarfism) with other skeletal abnormalities; fine, sparse hair (hypotrichosis); and abnormal immune system function (immune deficiency) that can lead to recurrent infections. People with cartilage-hair hypoplasia have unusually short limbs and short stature from birth. They typically have malformations in the cartilage near the ends of the long bones in the arms and legs (metaphyseal chondrodysplasia), which then affects development of the bone itself. Most people with cartilage-hair hypoplasia are unusually flexible in some joints, but they may have difficulty extending their elbows fully. Affected individuals have hair that is lighter in color than that of other family members because the core of each hair, which contains some of the pigment that contributes the hair's color, is missing. The missing core also makes each strand of hair thinner, causing the hair to have a sparse appearance overall. Unusually light-colored skin ( hypopigmentation), malformed nails, and dental abnormalities may also be seen in this disorder. The extent of the immune deficiency in cartilage-hair hypoplasia varies from mild to severe. Affected individuals with the most severe immune problems are considered to have severe combined immunodeficiency (SCID). People with SCID lack virtually all immune protection from bacteria, viruses, and fungi and are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by "opportunistic" organisms that ordinarily do not cause illness in people with a normal immune system. Most people with cartilage-hair hypoplasia, even those who have milder immune deficiency, experience infections of the respiratory system, ears, and sinuses.
    [Show full text]
  • A Disease-Linked Lncrna Mutation in Rnase MRP Inhibits Ribosome Synthesis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437572; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis Nic Roberston1, Vadim Shchepachev1, David Wright2, Tomasz W. Turowski1, Christos Spanos1, Aleksandra Helwak1, Rose Zamoyska2, David Tollervey1 1 Wellcome Centre for Cell Biology, University of Edinburgh, Edinburgh, UK 2 Ashworth Laboratories, Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, UK Keywords: protein-RNA interaction; RNA-binding sites; UV crosslinking; mass spectrometry; genetic disease; Cartilage Hair Hypoplasia; ribosome synthesis; T cell activation Running title: RNase MRP defects cause ribosomopathy Highlights: • Mutations in RMRP lncRNA impair pre-rRNA processing and T cell activation • Patient derived fibroblasts show impaired pre-rRNA processing • Cells with the most common disease-linked mutation have specific processing defects • Cytoplasmic ribosomes and intact RNase MRP complexes are also reduced in these cells 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437572; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Mutations in the human RMRP gene cause Cartilage Hair Hypoplasia (CHH), an autosomal recessive disorder characterized by skeletal abnormalities and impaired T cell activation.
    [Show full text]
  • Copy Number Variation and Huntington's Disease
    UNIVERSIDADE DE LISBOA FACULDADE DE MEDICINA DE LISBOA Copy number variation and Huntington’s disease Angelica Vittori Ramo das Ciências Biomédicas Especialidade – Neurociências Outubro 2013 UNIVERSIDADE DE LISBOA FACULDADE DE MEDICINA DE LISBOA Copy number variation and Huntington’s disease Candidata: Angelica Vittori Orientadores: Prof . Doutor Tiago Fleming Outeiro Doutor Flaviano Giorgini Doutor Edward J. Hollox Ramo das Ciências Biomédicas Especialidade – Neurociências Todas as afirmações efectuadas no presente documento são da exclusiva II responsabilidade do seu autor, não cabendo qualquer responsabilidade à faculdade de medicina de lisboa pelos conteúdos nela apresentados. A impressão são da exclusiva está dissertação foi aprovada pelo Conselho Cientifico da Faculdade de Medicina em reunião de 19 de Novembro de 2013. III Resumo A variação de número de cópias (CNV em inglês) é uma modificação de uma sequência de DNA que apresenta uma inserção ou deleção em comparação com um genoma de referência com um número de cópias de N = 2. Com um comprimento variável, desde 50 pares de bases até várias megabases, as CNVs identificadas têm um tamanho médio de ~ 3 Kb e representam cerca de 4% do genoma humano. As CNVs, como outras variações genéticas, podem afetar directamente os níveis de expressão dos genes afectados. Os efeitos indirectos na expressão genética podem ser causados por alterações da posição, interrompendo o quadro de leitura do gene ou posteriormente, perturbando as redes de regulação genética. Foi demonstrado que as CNVs são em grande parte responsáveis pela evolução humana e diversidade genética entre os indivíduos. A relevância das CNVs no genoma humano foi salientada por vários estudos de associação que mostraram o efeito das CNVs na susceptibilidade a doenças neurodegenerativas, doenças de características complexas, e por serem a principal causa do aparecimento de doenças mendelianas ou por conferirem um fenótipo benigno.
    [Show full text]
  • Alpha Defensin 1 Antibody / DEFA1 (R32739)
    Alpha Defensin 1 Antibody / DEFA1 (R32739) Catalog No. Formulation Size R32739 0.5mg/ml if reconstituted with 0.2ml sterile DI water 100 ug Bulk quote request Availability 1-3 business days Species Reactivity Human, Rat Format Antigen affinity purified Clonality Polyclonal (rabbit origin) Isotype Rabbit IgG Purity Antigen affinity Buffer Lyophilized from 1X PBS with 2.5% BSA, 0.025% sodium azide UniProt P59665 Applications Western Blot : 0.5-1ug/ml Limitations This Alpha Defensin 1 antibody is available for research use only. Western blot testing of 1) rat testis and 2) human HeLa lysate with Alpha Defensin 1 antibody at 0.5ug/ml. Predicted molecular weight ~10 kDa. Description Defensin, alpha 1, also known as human alpha defensin 1, human neutrophil peptide 1 (HNP-1) or neutrophil defensin 1 is a human protein that is encoded by the DEFA1 gene. Defensins are a family of antimicrobial and cytotoxic peptides thought to be involved in host defense. They are abundant in the granules of neutrophils and also found in the epithelia of mucosal surfaces such as those of the intestine, respiratory tract, urinary tract, and vagina. Members of the defensin family are highly similar in protein sequence and distinguished by a conserved cysteine motif. The protein encoded by this gene, defensin, alpha 1, is found in the microbicidal granules of neutrophils and likely plays a role in phagocyte-mediated host defense. Several alpha defensin genes are clustered on chromosome 8. This gene differs from defensin, alpha 3 by only one amino acid. This gene and the gene encoding defensin, alpha 3 are both subject to copy number variation.
    [Show full text]
  • DEFA1 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science DEFA1 Rabbit pAb Catalog No.: A6897 Basic Information Background Catalog No. Defensins are a family of antimicrobial and cytotoxic peptides thought to be involved in host A6897 defense. They are abundant in the granules of neutrophils and also found in the epithelia of mucosal surfaces such as those of the intestine, respiratory tract, urinary tract, and vagina. Observed MW Members of the defensin family are highly similar in protein sequence and distinguished by a 10KDa conserved cysteine motif. The protein encoded by this gene, defensin, alpha 1, is found in the microbicidal granules of neutrophils and likely plays a role in phagocyte-mediated host defense. Several alpha defensin genes are clustered on chromosome 8. This gene differs Calculated MW from defensin, alpha 3 by only one amino acid. This gene and the gene encoding defensin, 10kDa alpha 3 are both subject to copy number variation. Category Primary antibody Applications WB, IHC, IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 1667 P59665 IHC 1:50 - 1:100 Immunogen IF 1:50 - 1:100 Recombinant fusion protein containing a sequence corresponding to amino acids 1-94 of human DEFA1 (NP_004075.1). Synonyms DEFA1;DEF1;DEFA2;HNP-1;HP-1;HP1;MRS Contact Product Information 400-999-6126 Source Isotype Purification Rabbit IgG Affinity purification [email protected] Storage www.abclonal.com.cn Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using DEFA1 antibody (A6897) at 1:1000 dilution.
    [Show full text]
  • Papain-Like Protease Regulates SARS-Cov-2 Viral Spread and Innate Immunity
    Article Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity https://doi.org/10.1038/s41586-020-2601-5 Donghyuk Shin1,2,3, Rukmini Mukherjee1,2, Diana Grewe2, Denisa Bojkova4, Kheewoong Baek5, Anshu Bhattacharya1,2, Laura Schulz6, Marek Widera4, Ahmad Reza Mehdipour6, Georg Tascher1, Received: 30 April 2020 Paul P. Geurink7, Alexander Wilhelm4,8, Gerbrand J. van der Heden van Noort7, Huib Ovaa7,13, Accepted: 23 July 2020 Stefan Müller1, Klaus-Peter Knobeloch9, Krishnaraj Rajalingam10, Brenda A. Schulman5, Jindrich Cinatl4, Gerhard Hummer6,11, Sandra Ciesek4,8,12 & Ivan Dikic1,2,3,12 ✉ Published online: 29 July 2020 Check for updates The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread1,2. PLpro is also implicated in cleaving proteinaceous post-translational modifcations on host proteins as an evasion mechanism against host antiviral immune responses3–5. Here we perform biochemical, structural and functional characterization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (SCoV2-PLpro) and outline diferences with SARS-CoV PLpro (SCoV-PLpro) in regulation of host interferon and NF-κB pathways. SCoV2-PLpro and SCoV-PLpro share 83% sequence identity but exhibit diferent host substrate preferences; SCoV2-PLpro preferentially cleaves the ubiquitin-like interferon-stimulated gene 15 protein (ISG15), whereas SCoV-PLpro predominantly targets ubiquitin chains. The crystal structure of SCoV2-PLpro in complex with ISG15 reveals distinctive interactions with the amino-terminal ubiquitin-like domain of ISG15, highlighting the high afnity and specifcity of these interactions.
    [Show full text]
  • DEFA1) Antibody Catalogue No.:Abx005247
    Datasheet Version: 1.0.0 Revision date: 19 Nov 2020 Defensin Alpha 1, Neutrophil (DEFA1) Antibody Catalogue No.:abx005247 Western blot analysis of extracts of various cell lines, using DEFA1 antibody (abx005247) at 1/1000 dilution. Immunohistochemistry of paraffin-embedded rat heart using DEFA1 antibody (abx005247) at dilution of 1/100 (40x lens). Immunofluorescence analysis of HeLa cells using DEFA1 antibody (abx005247). Blue: DAPI for nuclear staining. DEFA1 Antibody is a Rabbit Polyclonal antibody against DEFA1. Defensins are a family of antimicrobial and cytotoxic peptides thought to be involved in host defense. They are abundant in the granules of neutrophils and also found in the epithelia of mucosal surfaces such as those of the intestine, respiratory tract, urinary tract, and vagina. Members of the defensin family are highly similar in protein sequence and distinguished by a conserved cysteine motif. The protein encoded by this gene, defensin, alpha 1, is found in the microbicidal granules of neutrophils and likely plays a role in phagocyte-mediated host defense. Several alpha defensin genesFor are clustered on chromosomeReference 8. This gene differs from defensin, alpha Only 3 by only one amino acid. This gene and the gene encoding defensin, alpha 3 are both subject to copy number variation. Target: DEFA1 Clonality: Polyclonal Reactivity: Human, Mouse, Rat v1.0.0 Abbexa Ltd, Cambridge, UK · Phone: +44 1223 755950 · Fax: +44 1223 755951 1 Abbexa LLC, Houston, TX, USA · Phone: +1 832 327 7413 www.abbexa.com · Email: [email protected] Datasheet Version: 1.0.0 Revision date: 19 Nov 2020 Tested Applications: WB, IHC, IF/ICC Host: Rabbit Recommended dilutions: WB: 1/500 - 1/2000, IHC: 1/50 - 1/100, IF/ICC: 1/50 - 1/100.
    [Show full text]
  • Downloaded from the Tranche Distributed File System (Tranche.Proteomecommons.Org) and Ftp://Ftp.Thegpm.Org/Data/Msms
    Research Article Title: The shrinking human protein coding complement: are there now fewer than 20,000 genes? Authors: Iakes Ezkurdia1*, David Juan2*, Jose Manuel Rodriguez3, Adam Frankish4, Mark Diekhans5, Jennifer Harrow4, Jesus Vazquez 6, Alfonso Valencia2,3, Michael L. Tress2,*. Affiliations: 1. Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Melchor Fernández Almagro, 3, rid, 28029, MadSpain 2. Structural Biology and Bioinformatics Programme, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, 28029, Madrid, Spain 3. National Bioinformatics Institute (INB), Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, 28029, Madrid, Spain 4. Wellcome Trust Sanger Institute, Wellcome Trust Campus, Hinxton, Cambridge CB10 1SA, UK 5. Center for Biomolecular Science and Engineering, School of Engineering, University of California Santa Cruz (UCSC), 1156 High Street, Santa Cruz, CA 95064, USA 6. Laboratorio de Proteómica Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares, CNIC, Melchor Fernández Almagro, 3, 28029, Madrid, Spain *: these two authors wish to be considered as joint first authors of the paper. Corresponding author: Michael Tress, [email protected], Tel: +34 91 732 80 00 Fax: +34 91 224 69 76 Running title: Are there fewer than 20,000 protein-coding genes? Keywords: Protein coding genes, proteomics, evolution, genome annotation Abstract Determining the full complement of protein-coding genes is a key goal of genome annotation. The most powerful approach for confirming protein coding potential is the detection of cellular protein expression through peptide mass spectrometry experiments. Here we map the peptides detected in 7 large-scale proteomics studies to almost 60% of the protein coding genes in the GENCODE annotation the human genome.
    [Show full text]
  • Anti-Alpha Defensin 1 Antibody (ARG65200)
    Product datasheet [email protected] ARG65200 Package: 100 μg anti-alpha Defensin 1 antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes alpha Defensin 1 Tested Reactivity Hu Tested Application IHC-P, WB Specificity This antibody is expected to equally recognize DEFA1 precursor and DEFA3 precursor. Host Goat Clonality Polyclonal Isotype IgG Target Name alpha Defensin 1 Antigen Species Human Immunogen C-DESLAPKHPGSRKN Conjugation Un-conjugated Alternate Names DEF1; Neutrophil defensin 1; HNP-1; HNP-2; HP-2; HP1; Defensin, alpha 1; MRS; DEFA2; HP2; HP-1 Application Instructions Application table Application Dilution IHC-P 3 - 6 µg/ml WB 1 - 3 µg/ml Application Note IHC-P: Antigen Retrieval: Steam tissue section in Citrate buffer (pH 6.0). WB: Recommend incubate at RT for 1h. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 10 kDa Properties Form Liquid Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA Preservative 0.02% Sodium azide Stabilizer 0.5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated www.arigobio.com 1/2 freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
    [Show full text]
  • Translation Factors and Ribosomal Proteins Control Tumor Onset and Progression: How?
    Oncogene (2014) 33, 2145–2156 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW Translation factors and ribosomal proteins control tumor onset and progression: how? F Loreni1, M Mancino2,3 and S Biffo2,3 Gene expression is shaped by translational control. The modalities and the extent by which translation factors modify gene expression have revealed therapeutic scenarios. For instance, eukaryotic initiation factor (eIF)4E activity is controlled by the signaling cascade of growth factors, and drives tumorigenesis by favoring the translation of specific mRNAs. Highly specific drugs target the activity of eIF4E. Indeed, the antitumor action of mTOR complex 1 (mTORc1) blockers like rapamycin relies on their capability to inhibit eIF4E assembly into functional eIF4F complexes. eIF4E biology, from its inception to recent pharmacological targeting, is proof-of-principle that translational control is druggable. The case for eIF4E is not isolated. The translational machinery is involved in the biology of cancer through many other mechanisms. First, untranslated sequences on mRNAs as well as noncoding RNAs regulate the translational efficiency of mRNAs that are central for tumor progression. Second, other initiation factors like eIF6 show a tumorigenic potential by acting downstream of oncogenic pathways. Third, genetic alterations in components of the translational apparatus underlie an entire class of inherited syndromes known as ‘ribosomopathies’ that are associated with increased cancer risk. Taken together, data suggest that in spite of their evolutionary conservation and ubiquitous nature, variations in the activity and levels of ribosomal proteins and translation factors generate highly specific effects. Beside, as the structures and biochemical activities of several noncoding RNAs and initiation factors are known, these factors may be amenable to rational pharmacological targeting.
    [Show full text]
  • 2016 Abstracts for Poster Presentation (PDF)
    1 Rat Bite Fever Resembling Rheumatoid Arthritis in a 46 Year Old Female Ripa Akter (Memorial University, St. John’s); Paul Boland (Memorial University, St. John’s); Peter Daley (Memorial University, St. John’s); Proton Rahman (Memorial University, St. John’s); Nayef Al Ghanim (Memorial University, St. John’s) A 46 year old female was admitted with a 1 week history of fever and symmetrical inflammatory polyarthritis associated with morning stiffness of 30 minutes duration. Past medical history was significant for seizure disorder, irritable bowel syndrome, chronic back pain and iron deficiency anemia. Family history was unremarkable for any rheumatological disease. On examination, she was febrile (38 degree celsius) with synovitis of her wrists, ankles, bilateral 5th metatarsophalangeal joints and left 3rd metacarpophalangeal joint. ESR and CRP were found to be elevated (76 MM/HR and 149 mg/L). Initial blood culture and serological tests including hepatitis B and C, parvovirus B19, HIV, Lyme disease and Neisseria gonorrhea were negative. Rheumatological work up including rheumatoid factor, anti-nuclear antibody, anti-cyclic citrullinated peptide antibody, anti-neutrophil cytoplasmic antibodies, anti-dsDNA antibody and compliment levels were all within normal limits. The patient was treated with a presumed diagnosis of rheumatoid arthritis with oral prednisone with mild improvement in synovitis. She was discharged home on triple therapy (methotrexate, sulphasalazine and hydroxychloroquine). The patient then returned to the hospital next day with worsening synovitis, fever 39 degree celcius and significant worsening of lower back pain. Sulphasalazine and methotrexate were discontinued due to mild elevation of liver enzymes. She continued to be febrile intermittently with ongoing elevated ESR of 124 MM/HR and CRP of 170 mg/L.
    [Show full text]
  • Lncrna-RMRP Promotes Proliferation, Migration and Invasion of Bladder Cancer Via Mir-206
    European Review for Medical and Pharmacological Sciences 2019; 23: 1012-1021 lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206 H.-L. CAO1, Z.-J. LIU2, P.-L. HUANG1, Y.-L. YUE3, J.-N. XI1 1Beijing Rehabilitation Hospital Affiliated to Capital Medical University, Beijing, China 2Shandong Provincial Western Hospital, Jinan, China 3Liaocheng People’s Hospital, Liaocheng, China Abstract. – OBJECTIVE: The incidence of an and American countries1. Recently, it has in- bladder cancer (BC) is common in the world, but creased its morbidity and rejuvenation. BC risk its detail mechanisms for occurrence and devel- factors are smoking and long-term exposure to opment remain unclear. Recently, long non-cod- industrial chemical products, which are related ing RNAs (lncRNAs) have been observed to play an important role in many different diseases. In to the changes in the gene level of patients; more- this research, we mainly explored the role of the over, the variety of apparent heredity is involved RNA component of mitochondrial RNA process- in the development of tumors2. The occurrence ing endoribonuclease (lncRNA-RMRP) in blad- and development of bladder cancer is a chronic der cancer. process with multi-factors and multi-steps3. Thus, MATERIALS AND METHODS: We used qRT- investigating the detail mechanisms involved in PCR to detect the expression of lncRNA-RMRP in bladder cancer patients and tumor cells, and BC bladder cancer will provide a novel strategy the clinical significance was also analyzed. The for its prevention and treatment. Long nonco- methyl thiazolyl tetrazolium (MTT) assay was ding RNAs (lncRNAs) are new members in the used to detect the cell proliferation, and we used oncology field, containing 200 nucleotide (nt)- transwell to detect the migration and invasion, long RNA molecules and stably existing in the after the lncRNA RMRP was inhibited.
    [Show full text]